Newgen Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 9 Year, 6 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.02 Cr
as on 14-12-2024
- Revenue 245.16%
(FY 2020)
- Profit 99.21%
(FY 2020)
- Ebitda 539.42%
(FY 2020)
- Net Worth -0.71%
(FY 2020)
- Total Assets 48.90%
(FY 2020)
About Newgen Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.02 Cr.
Naresh Kumar and Rupa Kumari serve as directors at the Company.
- CIN/LLPIN
U36900HP2016PTC001118
- Company No.
001118
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jan 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- LocationMandi, Himachal Pradesh
- Telephone
- Email Address
- Social Media-
What products or services does Newgen Biotech Private Limited offer?
Newgen Biotech Private Limited offers a wide range of products and services, including Common Disease Medicines, Anaemia Medicine, Nutraceuticals & Dietary Supplements, Fitness Supplements, Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Pharmaceutical Tablets, Nutritional Supplements, Pain Relief Drugs & Pharmaceuticals, Diclofenac.
Who are the key members and board of directors at Newgen Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naresh Kumar  | Director | 14-Jan-2016 | Current |
| Rupa Kumari | Director | 14-Jan-2016 | Current |
Financial Performance of Newgen Biotech.
Newgen Biotech Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 245.16% increase. The company also saw a substantial improvement in profitability, with a 99.21% increase in profit. The company's net worth dipped by a decrease of 0.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Newgen Biotech?
In 2020, Newgen Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Apr 2022 | ₹6.01 M | Open |
Others Creation Date: 29 Sep 2018 | ₹6.20 M | Open |
Others Creation Date: 08 May 2017 | ₹3.00 M | Open |
How Many Employees Work at Newgen Biotech?
Unlock and access historical data on people associated with Newgen Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Newgen Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Newgen Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
